Lackner Mark
- SEC CIK
- 0001777413
No open-market purchases or sales filed in the past year.
Current role at each company
- ZNTL Zentalis Pharmaceuticals, Inc.Chief Scientific Officeras of Feb 5, 2025
Open-market trades in the past year
Open-market purchases (P) and sales (S) filed in the last 365 days, not counting derivative securities or duplicate filings. Values leave out price outliers.
- Bought
- –
- 0 filings
- Sold
- –
- 0 filings
- Net
- –
- Bought minus sold
- Companies
- 0
- With open-market trades
Trades
Every Form 4 that lists Lackner Mark as a reporting owner, including filings made jointly with others, grouped by company. Each row adds up one type of transaction in one filing. Only open-market purchases (P) and sales (S) are shown by default.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Feb 5, 2025 (view filing) | Feb 3 | 2 days | Lackner MarkChief Scientific Officer | SSale | −14.4K | $1.71 | −$24.6K | −2.7%512.9K after | |
| Jan 3, 2025 (view filing) | Jan 2 | 1 day | Lackner MarkChief Scientific Officer | SSale | −4.41K | $3.12 | −$13.8K | −2.3%191.3K after | |
| Feb 5, 2024 (view filing) | Feb 2 | 3 days | Lackner MarkChief Scientific Officer | SSale | −1.58K | $11.54 | −$18.3K | −0.8%195.7K after |